{{Rsnum
|rsid=2279345
|Gene=CYP2B6
|Chromosome=19
|position=41009797
|Orientation=plus
|GMAF=0.2998
|Assembly=GRCh38
|GenomeBuild=38.1
|dbSNPBuild=141
|geno1=(C;C)
|geno2=(C;T)
|geno3=(T;T)
|Gene_s=CYP2B6
}}{{ population diversity
| geno1=(C;C)
| geno2=(C;T)
| geno3=(T;T)
| CEU | 35.4 | 50.4 | 14.2
| HCB | 51.5 | 36.8 | 11.8
| JPT | 39.8 | 53.1 | 7.1
| YRI | 64.1 | 33.1 | 2.8
| ASW | 59.6 | 35.1 | 5.3
| CHB | 51.5 | 36.8 | 11.8
| CHD | 41.3 | 47.7 | 11.0
| GIH | 68.3 | 28.7 | 3.0
| LWK | 59.1 | 36.4 | 4.5
| MEX | 60.3 | 37.9 | 1.7
| MKK | 52.6 | 39.1 | 8.3
| TSI | 44.6 | 44.6 | 10.9
| HapMapRevision=28
}}{{PMID Auto
|PMID=20639527
|Title=Haplotype structure of CYP2B6 and association with plasma efavirenz concentrations in a Chilean HIV cohort
|OA=1
}}

{{PMID|21694616}} CYP2B6 polymorphisms influence the plasma concentration and clearance of the methadone S-enantiomer.

{{on chip | 23andMe v1}}
{{on chip | 23andMe v2}}
{{on chip | 23andMe v3}}
{{on chip | 23andMe v4}}
{{on chip | FTDNA2}}
{{on chip | FTDNA}}
{{on chip | HumanOmni1Quad}}
{{on chip | Illumina Human 1M}}